Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2024
Reporting Period: Second Quarter ended June 30, 2024
This filing serves as a notification that the Company issued a press release on August 13, 2024, announcing its financial results for the second quarter of 2024. The filing includes a business update and details regarding a conference call to discuss these results.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. It references a press release (Exhibit 99.1) for the actual figures.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: The filing explicitly states that the information contained in the referenced press release is summary information and should be considered in the context of the Company's other SEC filings.
Material Changes
The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended June 30, 2024.
Guidance, Outlook, and Risks
Management Commentary: The Company announced a business update alongside the financial results and scheduled a conference call to discuss the second quarter performance.
Regulatory Disclosure: The information furnished in this Item 2.02 and Item 7.01 (Regulation FD Disclosure) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It will not be incorporated by reference into other filings unless specifically identified.
Risks/Contingencies: No specific risks or contingencies are detailed in this text. The filing includes a disclaimer that the information is not intended to constitute a determination that it is material or complete for investment decision-making.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release dated August 13, 2024) for specific revenue, net loss, and cash position figures.
- Verify the conference call details mentioned in the press release to hear management's commentary on the business update.
- Consult the Company's most recent Form 10-Q for the quarter ended June 30, 2024, for audited or reviewed financial statements, as this 8-K only summarizes the announcement.
- Confirm the liquidity position and runway, as this is critical for clinical-stage biotechnology firms not explicitly detailed in this cover sheet.